Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Hutchmed (HCM) Share News

Hutchmed China reports positive phase two fanregratinib study data

25th Jun 2026 11:25

(Alliance News) - Hutchmed China Ltd on Thursday reported positive phase two data for fanregratinib in patients with intrahepatic cholangiocarcinoma, showing clinically meaningful and durable responses in a registration-enabling study. Read More

Hutchmed highlights data for sovleplenib in rare blood disorder

12th Jun 2026 16:24

(Alliance News) - Hutchmed China Ltd on Friday said phase III trial results for its investigational drug sovleplenib showed significant efficacy and a favourable safety profile in patients with warm antibody autoimmune hemolytic anaemia, or wAIHA. Read More

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line

21st May 2026 16:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

5th May 2026 13:13

EARNINGS AND TRADING: AltynGold reports annual revenue surge

29th Apr 2026 19:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

Hutchmed begins phase-three trials of lymphoma therapy in China

23rd Mar 2026 10:21

(Alliance News) - Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China. Read More

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich

23rd Mar 2026 07:59

(Alliance News) - GSK makes regulatory progress in Japan for a cancer therapy, Anglo American moves to delist from the Swiss exchange as part of its restructuring, and Applied Nutrition reports strong interim growth while holding back on shareholder payouts. Read More

Hutchmed shares slide as recalls cancer treatment Tazverik

9th Mar 2026 10:49

(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen SA. Read More

Hutchmed China 2025 profit surges on divestment but revenue falls

5th Mar 2026 11:43

(Alliance News) - Hutchmed China Ltd on Thursday reported lower revenue for 2025, but reported sharply higher profit following a major divestment gain and said it expects oncology revenue growth in 2026. Read More

Hutchmed China shares rise as tumour treatment trial begins

4th Mar 2026 12:08

(Alliance News) - Hutchmed China Ltd on Wednesday said it had launched a Phase I/IIa clinical trial of its cancer treatment HMPL-A580. Read More

UK earnings, trading statements calendar - next 7 days

26th Feb 2026 14:45

Hutchmed China hails lung cancer trial results published in Lancet

14th Jan 2026 12:06

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More

Hutchmed China hails sovleplenib results for form of anaemia in China

7th Jan 2026 11:41

(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More

Hutchmed China kicks off phase three stage of pancreatic cancer trial

5th Jan 2026 10:45

(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

Hutchmed drug gains China priority review for bile duct cancer

29th Dec 2025 10:51

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More

Hutchmed China kicks off clinical development of ATTC candidate

17th Dec 2025 13:25

(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours. Read More

Hutchmed drugs stay on NRDL; Tazverik added to new insurance list

8th Dec 2025 11:15

(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More

Hutchmed completes Saffron trial enrolment, results due 2026

5th Nov 2025 11:48

(Alliance News) - Hutchmed China Ltd on Wednesday said patient enrolment has been completed for its phase 3 Saffron trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients, with topline results expected in the first half of 2026. Read More

Hutchmed China CFO Cheng is interim CEO as CEO Su takes health leave

26th Aug 2025 09:14

(Alliance News) - Hutchmed China Ltd on Tuesday said Chief Executive Officer Weiguo Su will take a leave of absence for health reasons. Read More

FTSE 100 Latest

Value10,605.63

Change121.41